Published in Vasc Surg on July 26, 1972
Spontaneous haemothorax associated with von Recklinghausen's disease: review of occurrence in Japan. Thorax (1997) 1.31
Spontaneous massive hemothorax in a patient with neurofibromatosis type 1 with successful transarterial embolization. Korean J Radiol (2012) 1.13
Complex vertebral arteriovenous fistula and ruptured aneurysm in neurofibromatosis: a therapeutically challenging case. Skull Base Surg (2000) 0.83
Aneurysmal rupture of the costo-cervical trunk in a patient with neurofibromatosis type 1: A case report. Int J Surg Case Rep (2013) 0.81
Spontaneous haemothorax: a cause of sudden death in von Recklinghausen's disease. Postgrad Med J (1998) 0.75
Fatal acute retropharyngeal hemorrhage in neurofibromatosis type 1. Forensic Sci Med Pathol (2017) 0.75
Surgical management of coronary artery stenosis and peripheral artery occlusive disease of the lower extremity in a patient with neurofibromatosis: report of a case. Surg Today (2011) 0.75
Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation (1990) 2.22
Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation (2000) 1.69
Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation (2000) 1.63
Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol (1984) 1.57
Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation (1983) 1.51
Influence of positive inotropic therapy on pulsatile hydraulic load and ventricular-vascular coupling in congestive heart failure. J Am Coll Cardiol (1990) 1.44
Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol (1992) 1.41
Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation (1978) 1.35
Extent of myocardial fibrosis and cellular hypertrophy in dilated cardiomyopathy. Am J Cardiol (1986) 1.32
Aorto-left atrial fistula. A reversible cause of acute refractory heart failure. Chest (1997) 1.23
Human myocardial histologic characteristics in congestive heart failure. Circulation (1983) 1.23
The arrhythmogenic effects of caffeine in human beings. N Engl J Med (1983) 1.22
Cocaine-induced coronary-artery dissection. N Engl J Med (1994) 1.21
Prolonged atrial conduction. A major predisposing factor for the development of atrial flutter. Circulation (1978) 1.20
Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation (1984) 1.18
Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med (1980) 1.17
Cardiovascular abnormalities associated with adult polycystic kidney disease. Ann Intern Med (1984) 1.16
The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation (1977) 1.15
Altered collagen composition in a prolapsing mitral valve with ruptured chordae tendineae. Am J Med (1979) 1.12
Captopril in primary pulmonary hypertension. Circulation (1983) 1.12
Changes in diastolic time with various pharmacologic agents: implication for myocardial perfusion. Circulation (1979) 1.12
Cardiovascular effects of ophthalmic timolol. Ann Intern Med (1986) 1.10
Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol (1993) 1.09
Hemodynamic changes after meals and placebo treatment in chronic congestive heart failure. Am J Cardiol (1986) 1.07
Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension. Ann Intern Med (1982) 1.04
The spectrum of cardiac defects in the Ehlers-Danlos syndrome, types I and III. Ann Intern Med (1980) 1.04
The hemodynamic effects of ibopamine, a dopamine congener, in patients with congestive heart failure. Pharmacotherapy (1986) 1.02
Drugs five years later. Dobutamine. Ann Intern Med (1983) 1.02
Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose. Ann Intern Med (1981) 1.01
Dissimilar atrial rhythms. A patient with interatrial block. Br Heart J (1977) 1.01
Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll Cardiol (1998) 0.96
Persistent left superior vena cava: unusual wave contour of left jugular vein as the presenting feature. Am Heart J (1990) 0.96
Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol (1984) 0.93
Interatrial conduction (activation) times. Am J Cardiol (1979) 0.93
The noninvasive localization of ventricular pacing sites by radionuclide phase imaging. Circulation (1984) 0.92
Nitrate tolerance. Am Heart J (1985) 0.92
Magnesium content of serum, circulating mononuclear cells, skeletal muscle, and myocardium in congestive heart failure. Circulation (1989) 0.91
The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. Am Heart J (1983) 0.90
Hemodynamic-inotropic response to beta-blocker with intrinsic sympathomimetic activity in patients with congestive cardiomyopathy. Circulation (1986) 0.89
Early changes in human myocardial nuclei after doxorubicin. Cancer (1983) 0.88
Effect of increased adrenergic activity on the relationship between electrical and mechanical systole. Circulation (1981) 0.88
The effect of left atrial histology and dimension on P wave morphology. J Electrocardiol (1983) 0.88
Doxorubicin cardiotoxicity. Cancer Treat Rev (1982) 0.86
Central and regional hemodynamic effects of flosequinan for congestive heart failure. Am J Cardiol (1989) 0.86
Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure. Am J Cardiol (1980) 0.86
Postoperative pericarditis following thymectomy for myasthenia gravis. A prospective study. Chest (1983) 0.86
Amrinone in severe congestive heart failure: another look at an intriguing new cardioactive drug. J Pharmacol Exp Ther (1984) 0.85
Rest and exercise cardiovascular effects of terazosin in congestive heart failure. Am J Cardiol (1990) 0.85
Drug-induced conditioning in congestive heart failure. Circulation (1982) 0.84
Cardiac function in Duchenne's muscular dystrophy. Results of 10-year follow-up study and noninvasive tests. Am J Med (1982) 0.84
Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. Am J Cardiol (1983) 0.83
Placebo treatment in congestive heart failure. Cardiology (1992) 0.83
Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J (1980) 0.83
Temporary atrial standstill. Am Heart J (1979) 0.83
An electrophysiologic study of swallowing-induced tachycardia. Chest (1978) 0.83
Serum and tissue magnesium concentrations in patients with heart failure and serious ventricular arrhythmias. Ann Intern Med (1990) 0.82
The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J (1983) 0.82
An analysis of the determinants of exercise performance in congestive heart failure. Am Heart J (1987) 0.82
Development of pharmacodynamic tolerance to prozosin in congestive heart failure. Am J Cardiol (1979) 0.82
Autonomic tone of patients during an electrophysiological catheterization. The role of autonomic influences on the reproducibility of sinus node function studies. Am Heart J (1980) 0.82
Medical therapy of end-stage congestive and ischemic cardiomyopathy. Cardiovasc Clin (1988) 0.82
Increased diastolic time: a possible important factor in the benefical effect of propranolol in patients with coronary artery disease. J Cardiovasc Pharmacol (1980) 0.82
Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs. Am J Cardiol (1985) 0.82
A paucity of chronic electrocardiographic changes with adriamycin therapy. J Electrocardiol (1978) 0.82
Diastolic time in congestive heart failure. Am Heart J (1987) 0.82
Dobutamine increases cardiac output of the total artificial heart. Implications for vascular contribution of inotropic agents to augmented ventricular function. Circulation (1991) 0.81
Position as a variable for cardiovascular responses during exercise. Clin Cardiol (1987) 0.81
The electrophysiologic effects of upright posture. Am Heart J (1984) 0.81
Prevention of bedrest-induced physical deconditioning by daily dobutamine infusions. Implications for drug-induced physical conditioning. J Clin Invest (1985) 0.80
Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine. J Natl Cancer Inst (1983) 0.80
Influence of exercise on coronary sinus blood flow determinations. Am J Cardiol (1987) 0.80
Nifedipine in congestive heart failure: effects on resting and exercise hemodynamics and regional blood flow. Am Heart J (1984) 0.80
Hemodynamic effects of smoking in congestive heart failure. Am J Med Sci (1988) 0.79
Electrophysiologic studies of perphenazine and protriptyline in a patient with psychotropic drug-induced ventricular fibrillation. Am J Med (1979) 0.79
Heart rate responsiveness after sustained chronotropic stimulation with a beta 1-adrenergic receptor agonist. J Lab Clin Med (1983) 0.79
In vivo validation of the origin of the esophageal electrocardiogram. J Am Coll Cardiol (1986) 0.79
Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial. Am J Cardiol (1990) 0.79
Reproducibility of echocardiography in chronic congestive heart failure. J Clin Ultrasound (1980) 0.79
Beneficial effects of nifedipine on rest and exercise myocardial energetics in patients with congestive heart failure. Circulation (1984) 0.79
The dopamine congener, ibopamine, in congestive heart failure. J Cardiovasc Pharmacol (1984) 0.79
Comparison between electrophysiologic studies and ambulatory monitoring in patients with syncope. J Electrocardiol (1983) 0.79
Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. J Pharmacokinet Biopharm (1984) 0.78
Regional hemodynamic effects of clonidine in congestive heart failure. J Cardiovasc Pharmacol (1985) 0.78
Cardiomyoplasty: is it time to wrap it up? J Am Coll Cardiol (1996) 0.78
The relationship between plasma dobutamine concentrations and cardiovascular responses in cardiac failure. Am J Med (1979) 0.78
Regression of myocardial cellular hypertrophy with vasodilator therapy in chronic congestive heart failure associated with idiopathic dilated cardiomyopathy. Am J Cardiol (1983) 0.78
Dissociation between ACE activity and autonomic response to ACE inhibition in patients with heart failure. Am Heart J (2000) 0.78
Electrolyte disturbances in chronic heart failure: metabolic and clinical aspects. Clin Cardiol (1995) 0.78
Failure of percutaneous transluminal coronary angioplasty to stimulate platelet and prostaglandin activity. Cathet Cardiovasc Diagn (1985) 0.78
Effects of commonly used cardioactive drugs on atrial and sinoatrial conduction in man. J Cardiovasc Pharmacol (1980) 0.78
Dobutamine pharmacokinetics in severe heart failure. Clin Pharmacol Ther (1978) 0.77
Depressed aerobic enzyme activity of skeletal muscle in severe chronic heart failure. J Lab Clin Med (1991) 0.77
Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients. J Am Coll Cardiol (2000) 0.77
Survival in congestive heart failure during treatment with drugs with positive inotropic actions. Circulation (1987) 0.77
The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure. Am J Med Sci (1986) 0.77
Electrophysiologic and antiarrhythmic effects of nitroglycerin in man. J Cardiovasc Pharmacol (1981) 0.77
Usefulness of hydralazine to withdraw from dobutamine in severe congestive heart failure. Am J Cardiol (1991) 0.77
Improvement of human myocardial mitochondria after dobutamine: a quantitative ultrastructural study. J Pharmacol Exp Ther (1980) 0.77